SCHEMBL4720215

SCHEMBL4720215

CN1Cc2cc(OCCCN3CCCCC3)ncc2C(c2ccccc2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 20/20 1.00
HRH3 Q9Y5N1 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722100 0.90 HRH3 (1.00) SLC6A4HRH3
SCHEMBL4723377 0.90 SLC6A4 (1.00) SLC6A4HRH3
SCHEMBL4719773 0.89 HRH3 (1.00) SLC6A4HRH3
SCHEMBL4719682 0.89 SLC6A4 (0.81) SLC6A4HRH3
SCHEMBL4720882 0.89 SLC6A4 (1.00) SLC6A4HRH3
SCHEMBL4719830 0.89 HRH3 (1.00) SLC6A4HRH3
SCHEMBL4720198 0.87 SLC6A4 (1.00) SLC6A4HRH3
SCHEMBL4721782 0.86 SLC6A4 (1.00) SLC6A4HRH3
SCHEMBL4720086 0.84 SLC6A4 (0.87) SLC6A4HRH3
SCHEMBL4721189 0.82 SLC6A4 (1.00) SLC6A4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP claimed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US claimed
EP-1899334-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP claimed
WO-2006138714-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO claimed
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 US claimed
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
EP-1899334-B1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
US-7417054-B2 Naphthyridine compounds JANSSEN PHARMACEUTICA N.V. (BG) 2008-08-26 US disclosed
EP-1899334-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
WO-2006138714-A2 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO disclosed
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287292-A1 NAPHTHYRIDINE COMPOUNDS HRH3, HRH4, HRH1 SLC6A4 10/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.